The efficacy and safety of Rivaroxaban and Nadroparin for thromboprophylaxis after pulmonary surgery for cancer: a single, randomized, single-blind, parallel control clinical study.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038186

Enrollment

Unknown

Registered

2020-09-12

Start date

2020-12-01

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Thromboembolism

Interventions

Rivaroxaban:Take Rivaroxaban

Nadroparin:Take Nadroparin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Post pulmonary surgery (shown malignant with frozen slice); 2. Caprini scores equal to or more than 5.

Exclusion criteria

Exclusion criteria: 1. Aged < 18 years; 2. Concomitant presence of proximal deep vein thrombosis or pulmonary embolism before surgery; 3. Using anticoagulation or antiplatelet drugs; 4. Any absolute contraindication to anticoagulant treatment; 5. Allergy to anticoagulation drugs; 6. Pregnancy or breast-feeding; 7. Creatinine clearance <= 30 ml/min, according to Cockcroft-Gault equation; 8. Cirrhosis Child-Pugh score B or C; 9. Liver disease associated with coagulopathy and high risk of bleeding; 10. Any other contraindication to rivaroxaban as per local SmPC; 11. Failure to provide written informed consent

Design outcomes

Primary

Measure	Time frame
Incidence of VTE;	—

Secondary

Measure	Time frame
Major bleeding;	—

Countries

China

Contacts

Public ContactLei Shen

Shanghai Pulmonary Hospital

sh_leisen@126.com+86 18321651636

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026